Building a World-Class Innovative Therapeutic Biologics Industry in China
BIO and R&D Based Pharmaceutical Association Committee (RDPAC) have commissioned a multi-year study on best practices in building an innovative therapeutic biologics industry in China, exploring success and failures in other markets. Key recommendations are made with the intention of providing a foundation for revision on the next five-year plan as it relates to biotechnology, one of China’s seven Strategic Emerging Industries (SEIs)
China’s New Party Leadership, Implications for Central Planning and Regulation
This past March, China went through a historic leadership transition. As the new president, Xi Jinping, takes the helm and ministries like the China Food & Drug Administration (CFDA) are elevated in importance, what are the implications for the biotechnology industry in China?
Looking Forward: 13th Five-Year Plan & Its Investment in Innovation
As China’s 12th Five-Year Plan concludes in 2015, the country begins to lay the groundwork for the 13th Five-Year Plan for 2016-2020. This panel will explore lessons learned, areas of strength, areas for improvement, and where industry can support central planners moving forward.